An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Sponsor: Mirum Pharmaceuticals, Inc.
This PHASE3 trial investigates Progressive Familial Intrahepatic Cholestasis (PFIC) and is currently completed. Mirum Pharmaceuticals, Inc. leads this study, which shows 17 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jul 2025 — Sep 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Mar 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 12 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Jun 2024 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Sep 2022 — Nov 2023 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2022 — Jul 2022 [monthly]
Enrolling By Invitation PHASE3
-
Mar 2021 — Jan 2022 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Enrolling By Invitation PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2020 — Oct 2020 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2020 — Jul 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Jan 2020 — Feb 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mirum Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .